Results 31 to 40 of about 199,032 (289)

Immune Checkpoint Inhibitors

, 2023
Immune Checkpoint Inhibitors - New Insights and Recent Progress explores a vast array of subjects related to immune checkpoint inhibitors and presents novel insights in this emerging field.

core   +1 more source

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

Journal of Experimental & Clinical Cancer Research, 2021
Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies.
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime   +6 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?

Frontiers in Oncology, 2022
Immune checkpoint inhibitors have improved the survival in patients affected by an increasing number of malignancies, but they may also trigger various autoimmune side-effects, including endocrinopathies.
Agnese Barnabei, Lidia Strigari, Andrea Corsello, Rosa Maria Paragliola, Luca Falzone, Roberto Salvatori, Salvatore Maria Corsello, Salvatore Maria Corsello, Francesco Torino   +8 more
doaj   +1 more source

Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0

, 2022
Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies.
Andréia Cristina de Melo, Sergio Jobim de Azevedo, Paulo Marcelo Gehm Hoff, Aknar Calabrich, Rodrigo Ramella Munhoz, Luiza Dib Batista Bugiato Faria, Gilberto de Castro, Guilherme Nader Marta, Antonio Carlos Buzaid, Vladmir Cláudio Cordeiro de Lima, Romualdo Barroso-Sousa, Artur Katz, Guilherme Harada, Carlos Henrique dos Anjos, William Nassib William, Carlos Gil Ferreira, Elimar Elias Gomes, Mariana Laloni, Clarissa Maria de Cerqueira Mathias, Clarissa Baldotto, Alberto Julius Wainstein, Fernando Moura, Gustavo dos Santos Fernandes   +22 more
core   +1 more source

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab

Frontiers in Oncology, 2020
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity.
S. Morteza Seyed Jafari, Laurence Feldmeyer, Robert E. Hunger   +2 more
doaj   +1 more source

Immune Checkpoint Inhibitors in NSCLC [PDF]

Current Treatment Options in Oncology, 2014
Lung cancer is the leading cause of cancer-related mortality worldwide. Cytotoxic chemotherapy and tyrosine kinase inhibitors provide palliation and prolong survival, however, the median survival for patients with metastatic disease remains poor and more effective therapies are needed.
Douglas B, Johnson, Matthew J, Rioth, Leora, Horn   +2 more
openaire   +2 more sources

The role of immune checkpoint inhibitors in the development and treatment of infectious processes [PDF]

Клиническая практика
The incidence and prevalence of oncological diseases, which are the second most frequent cause of death, is steadily increasing among the population of the Russian Federation.
Dilya A. Mustafina, Aisylu N. Bagautdinova, Milyausha M. Zinatullina, NIkita A. Gorbunov, Elvina T. Zainetdinova, Diana I. Bukharmetova, Daniil Yu. Leonov, Aibike G. Pirmagomedova, Anna E. Chernyshova, Maria P. Markhanos, Anna G. Abgaryan, Arina S. Arustamyan, Konstantin S. Chavro, Farzonakhon Mirzojonova   +13 more
doaj   +1 more source

A Role of Therapy that Targets Immune Checkpoint Proteins for the Treatment of Melanoma Brain Metastasis, Liver, Breast, Pancreatic Cancer and Pancreatic Adenocarcinoma

مجله كليه طب الكندي, 2022
Checkpoint inhibitors are a type of immune therapy used to treat different types of cancers. These drugs block different checkpoint proteins, for example, CTLA-4, PD-1, and PD-L1 inhibitors.
Smaa Elsayed Mohammed, Basma Aml Youssef, Doaa Alaa Ghonai, Eman Fares Ahmed, Esraa Gharieb Mohammed, Mai Ashraf Abdo, Mai Essam Mohammed, Rana Gharieb Hassan, Reem Mohammed Mohammed, Rofida Ahmed Abd Al-Azeem, Sarah Adel Swelem, Sarah Ouda Salman, Sarah Mohammed Al-aiyq, Toka Taha Taha, Zainab Khalid Moawad   +14 more
doaj   +1 more source

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Frontiers in Pharmacology, 2023
In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade.
Zherui Liu, Zherui Liu, Yun Zhu, Huan Xie, Zhengsheng Zou, Zhengsheng Zou, Zhengsheng Zou   +6 more
doaj   +1 more source

Nephrotoxicity of checkpoint inhibitors; a current challenge [PDF]

Journal of Nephropharmacology
Immune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system.
Samaneh Zandifar, Mahshid Imankhan, Padideh Daneii, Ali Azarpey, Leila Alem   +4 more
doaj   +1 more source